Natera

NTRA Large Cap

Healthcare · Diagnostics & Research

Updated: Apr 5, 2026, 00:03 UTC

$207.98

+2.35% today

52W: $125.38 – $256.36

52W Low: $125.38 Position: 63.1% 52W High: $256.36

🔗 Compare Brokers Best Broker for Beginners →

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

12.78x

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$29.5B

Market Capitalization

Revenue Growth

39.8%

YoY Revenue Growth

Profit Margin

-9.03%

Net profit margin

ROE

-14.32%

Return on Equity

Beta

1.68

Market sensitivity

Short Interest

2.43%

% of float sold short

Avg. Volume

1,205,516

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Strong Buy

19 analysts

Avg. Price Target

$259.11

+24.58% upside

Target Range

$190.00 – $300.00

★ Smart Money Investors

♣ Druckenmiller

This stock is held by one or more of our 15 tracked Smart Money managers. Click a name to view their full portfolio.

About the Company

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and

Sector: Healthcare Industry: Diagnostics & Research Country: United States Employees: 6,135 Exchange: NMS